- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | PROVECTUS BIOPHARMACEUTICALS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 28.03. | PROVECTUS BIOPHARMACEUTICALS, INC. - 10-K, Annual Report | 1 | SEC Filings | ||
| 27.03. | Provectus Biopharmaceuticals Inc.: Provectus Biopharmaceuticals Announces Exclusive Worldwide License Agreement with University of Miami for Photodynamic Antimicrobial Treatment of Different Eye Infections with Rose Bengal Sodium | 50 | GlobeNewswire (Europe) | New Provectus Spinout Company Would Commercialize Combination Therapy of University's Light Source Medical Device and Provectus's Pharmaceutical-Grade Rose Bengal Sodium KNOXVILLE, TN, March 27,... ► Artikel lesen | |
| 26.03. | PROVECTUS BIOPHARMACEUTICALS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.03. | Provectus Biopharmaceuticals Inc.: Provectus Biopharmaceuticals Announces Notices of Allowance and Award for U.S. Patents of Rose Bengal Sodium in Virology, Pediatric Solid Tumor Cancers, and Vaccines | 219 | GlobeNewswire (Europe) | KNOXVILLE, TN, March 12, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. ("Provectus" or the "Company") (OTCQB: PVCT) today announced that the United States Patent and Trademark Office... ► Artikel lesen | |
| 22.02. | PROVECTUS BIOPHARMACEUTICALS, INC. - 8-K, Current Report | 3 | SEC Filings | ||
| 15.02. | Provectus Biopharmaceuticals Inc.: Provectus Biopharmaceuticals Announces First Quarter 2024 Conference Call | 3 | GlobeNewswire (USA) | ||
| 15.02. | PROVECTUS BIOPHARMACEUTICALS, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 18.12.23 | Provectus Biopharmaceuticals Inc.: Provectus Biopharmaceuticals Announces Notice of Allowance of First U.S. Patent of Rose Bengal Sodium for Use as Anticancer and Antiviral Vaccine Adjuvant | 182 | GlobeNewswire (Europe) | KNOXVILLE, TN, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the United States Patent and Trademark Office (USPTO) has allowed patent application 17/488,430, titled... ► Artikel lesen | |
| 15.11.23 | Provectus Biopharmaceuticals Inc.: Provectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy PV-10 for Advanced Cutaneous Melanoma | 328 | GlobeNewswire (Europe) | KNOXVILLE, TN, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today provided updated data from an ongoing Phase 1b/2 clinical trial of investigational cancer immunotherapy PV-10 (rose bengal... ► Artikel lesen | |
| 14.11.23 | PROVECTUS BIOPHARMACEUTICALS, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 13.11.23 | Provectus Biopharmaceuticals Inc.: Provectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy PV-10 for Metastatic Uveal Melanoma | 506 | GlobeNewswire (Europe) | KNOXVILLE, TN, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today provided updated data from an ongoing Phase 1 clinical trial of investigational cancer immunotherapy PV-10 (rose bengal... ► Artikel lesen | |
| 28.06.23 | Provectus Biopharmaceuticals Inc.: Provectus Biopharmaceuticals Establishes Research Collaboration with University of Tennessee College of Veterinary Medicine to Investigate Pharmaceutical-Grade Small Molecule Immunotherapy Rose Bengal Sodium for Canine S | 207 | GlobeNewswire (Europe) | KNOXVILLE, TN, June 28, 2023 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company has initiated a new sponsored research program with the University of Tennessee College of... ► Artikel lesen | |
| 26.06.23 | Provectus Biopharmaceuticals Inc.: Provectus Biopharmaceuticals Announces Stockholder Approval to Undertake Reverse Split of Outstanding Equities and Reduce Number of Authorized Equities by Same Ratio | 316 | GlobeNewswire (Europe) | KNOXVILLE, TN, June 26, 2023 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company's shareholders have approved the proposals of Provectus's Board of Directors (Board) to seek... ► Artikel lesen |
14 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVO NORDISK | 115,84 | -0,03 % | Erwerb der Cardior Pharmaceuticals GmbH durch die Novo Nordisk A/S freigegeben | Das Bundeskartellamt hat die geplante Übernahme sämtlicher Anteile der Cardior Pharmaceuticals GmbH mit Sitz in Hannover durch die dänische Novo Nordisk A/S freigegeben. Cardior ist ein Biotech-Unternehmen... ► Artikel lesen | |
| AURORA CANNABIS | 6,035 | -0,33 % | Aurora Cannabis & Canopy Growth: Deshalb ziehen sie an | Die Aurora Cannabis-Aktie (WKN: A2P4EC) und die Aktie von Canopy Growth (WKN: A140WQA) haben am Donnerstag plötzlich einen massiven Kurssprung von über +20% vollführt. Das steckt hinter dem rasanten... ► Artikel lesen | |
| CANOPY GROWTH | 7,490 | +0,40 % | Cannabis-Aktien: Cannabis-Rally zerfällt zu Staub. Tilray und Canopy im Fokus. | Anzeige / WerbungDer Erwartungen waren hoch. Die Enttäuschung ist nun mindestens genauso groß.Der Erwartungen waren hoch. Die Enttäuschung ist nun mindestens genauso groß. Der Start in die Berichtssaison... ► Artikel lesen | |
| TILRAY BRANDS | 1,620 | +0,06 % | Is Tilray Stock a Buy in the New Bullish Market? | ||
| VERTEX PHARMACEUTICALS | 369,90 | -0,08 % | Vertex Pharmaceuticals Incorporated: Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain | Rolling submission for suzetrigine moderate-to-severe acute pain NDA granted by FDA; first module submitted and on track to complete filing this quarter -
Successful completion of end-of-phase 2... ► Artikel lesen | |
| TAAT GLOBAL ALTERNATIVES | 0,210 | +28,44 % | TAAT Global Alternatives Inc.: TAAT Announces Shares for Debt Settlement | ||
| CRONOS GROUP | 2,254 | +1,53 % | Cronos Group Inc. - 8-K, Current Report | ||
| DIGICANN VENTURES | 0,011 | -8,70 % | Digicann Ventures Inc: Digicann to extend maturity date of debentures by 1 yr | ||
| SANOCHEMIA PHARMAZEUTIKA | - | - | Nachlese: Magnus Brunner vs. FMA" EOSS holt nach Sanochemia auch BDI BioEnergy; Bettina Pfluger (Christian Drastil) | Um 12:12 liegt der ATX mit +0.03 Prozent im Plus bei 3452 Punkten (Ultimo 2023: 3435, 0.49% ytd). Topperformer der PIR-Group sind Addiko Bank mit +1.82% auf 15.425 Euro, dahinter DO&CO mit +1.79% auf... ► Artikel lesen | |
| WPD PHARMACEUTICALS | 0,027 | 0,00 % | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA - 18.04.2024 | The following instruments on XETRA do have their first trading 18.04.2024 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 18.04.2024
Aktien
1 US23341C1036 DNB Bank ASA ADR
2... ► Artikel lesen | |
| ORGANIGRAM | 1,780 | +0,56 % | 50 - 200 % * X mit Cannabis Aktien? Aurora, Tilray, Organigram, Planet 13, High Tide, Village Farms | Sind Sie daran interessiert, in Cannabis-Aktien zu investieren, und fragen Sie sich nach den möglichen Renditen? In diesem Kommentar besprechen wir die Möglichkeit, mit Unternehmen wie Aurora Cannabis... ► Artikel lesen | |
| GREEN THUMB INDUSTRIES | 11,670 | -0,26 % | Green Thumb Industries: Aktie muss nachsetzen | Anzeige / WerbungLetztendlich blieben aber positive Impulse auf den Aktienkurs aus. Dabei wären diese dringend notwendig.Green Thumb Industries veröffentlichte am gestrigen Mittwoch (28. Februar) die... ► Artikel lesen | |
| MYDECINE INNOVATIONS GROUP | 0,012 | -27,27 % | Mydecine Innovations Group Inc - Closing of Share for Debt Settlement | Mydecine Innovations Group Inc - Closing of Share for Debt Settlement
PR Newswire
LONDON, United Kingdom, April 16
MYDECINE INNOVATIONS GROUP INC.ANNOUNCES CLOSING OF... ► Artikel lesen | |
| SINOPHARM | 2,365 | -1,91 % | SINOPHARM (01099): NOTICE OF BOARD MEETING | ||
| ASTRIA THERAPEUTICS | 9,750 | -7,50 % | Astria Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update | BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today reported... ► Artikel lesen |
Das Unternehmen PROVECTUS BIOPHARMACEUTICALS INC kann der Branche Pharma zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,045 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
